View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsOncoSec Medical 배당 및 자사주 매입배당 기준 점검 0/6OncoSec Medical 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-432.7%자사주 매입 수익률총 주주 수익률-432.7%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 16+ 2 more updatesOncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial OfficerOncoSec Medical Incorporated announced that on June 12, 2023, George Chi was terminated for cause as an employee and Chief Financial Officer of the company, effective immediately.공고 • Jun 03OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price RequirementOn June 1, 2023, OncoSec Medical Incorporated (the Company") received notice (the Notice") from the Nasdaq Stock Market LLC (Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the listing of the Company's common stock, which will continue to trade at this time on the Nasdaq Capital Market under the symbol ONCS." In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until November 28, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180 calendar day period. In the event the Company does not regain compliance by November 28, 2023, the Company may be eligible for an additional 180 calendar day grace period if it meets the continued listing requirement for market value of publicly held shares ($1 million) and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not regain compliance within the allotted compliance period(s), Nasdaq will provide notice that the Company's common stock will be subject to delisting from the Nasdaq Capital Market. In that event, the Company may appeal such delisting determination to a hearings panel. The Company intends to monitor the closing bid price of its common stock and consider options to resolve its noncompliance with the minimum bid price requirement.공고 • May 19OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,408,384 Price\Range: $0.945 Discount Per Security: $0.0709 Transaction Features: Registered Direct Offering공고 • May 17Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical ProgramOncoSec Medical Incorporated announced a Type C meeting held with the US Food and Drug Administration (FDA) on May 15, 2023. The purpose of the meeting was to discuss the trial design for a planned randomized, open-label Phase 2 clinical trial in patients with high-risk, resectable melanoma to evaluate the neoadjuvant treatment combination of the Company's tavokinogene telseplasmid, a plasmid encoding human interleukin 12 (IL-12), administered intratumorally by electroporation (TAVO(TM)-EP) with intravenous KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy. The meeting with the FDA represents an important next step on the Company's path to pursue clinical development of TAVO(TM)-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting. The Company discussed with the FDA the proposed design of a global randomized Phase 2 trial, which includes a primary endpoint of pathological complete response (pCR) rate and secondary endpoints including event-free survival (EFS) and pathological major response (pMR) rate. As discussed with the FDA, a single arm run-in stage is planned to confirm the appropriate neoadjuvant dosing schedule and allow the collection of mechanistic biomarker data to further evaluate the mechanism of action of TAVO(TM-EP as a trigger for anti-tumor immune effector functions. The Company's discussion with the FDA follows the release of interim data from an ongoing investigator-sponsored trial (IST) led by Dr. Ahmad Tarhini at the H. Lee Moffit Cancer Center & Research Institute evaluating TAVO(TM)- EP in combination with intravenous nivolumab, which showed encouraging clinical and pathological response rates. The Company appreciates the productive meeting with the FDA and the agency's feedback on the trial design and potential strategies for future registrational paths.Board Change • Jan 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Stephany Foster was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Oct 04OncoSec to cut workforce by 45% as part of corporate restructuringOncoSec Medical (NASDAQ:ONCS) on Tuesday said it would reduce its workforce by about 45% as part of a restructuring intended to focus expenses on the development of its lead clinical candidate Tavo. The company is evaluating Tavo in a phase 2b trial called KEYNOTE-695 for the treatment of metastatic melanoma, the most serious type of skin cancer. "Since joining as CEO my focus has been on reviewing all aspects of our technology and pipeline. This led to the conclusion that an operational restructuring and strategic pipeline refocus is the best course of action," ONCS top boss Robert Arch said in a statement. The company said results of the KEYNOTE-695 trial's secondary goal was expected in Q4 of this year, while results from the main goal was expected in Q1 2023. ONCS stock earlier closed -2% at $0.49.Price Target Changed • Apr 27Price target decreased to US$5.00Down from US$10.00, the current price target is provided by 1 analyst. New target price is 536% above last closing price of US$0.79. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.99 next year compared to a net loss per share of US$1.37 last year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim DeMesa was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Mar 17Price target decreased to US$5.00Down from US$9.50, the current price target is provided by 1 analyst. New target price is 404% above last closing price of US$0.99. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$1.37 next year compared to a net loss per share of US$1.37 last year.Board Change • Dec 15Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Chairperson Margaret Dalesandro was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Executive Departure • Aug 18Interim CEO & COO Brian Leuthner has left the companyOn the 13th of August, Brian Leuthner's tenure as Interim CEO & COO of the company ended after less than a year in the role. As of June 2021, Brian still personally held 34.39k shares (US$97k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.92 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Brian's leadership, the company delivered a total shareholder return of -20%.Breakeven Date Change • Aug 01Forecast to breakeven in 2024The 3 analysts covering OncoSec Medical expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$71.1m in 2024. Average annual earnings growth of 54% is required to achieve expected profit on schedule.Executive Departure • Jun 29President, CEO & Director Daniel O'Connor has left the companyOn the 25th of June, Daniel O'Connor was replaced as CEO by Brian Leuthner after 3.6 years in the role. As of March 2021, Daniel still personally held 80.52k shares (US$384k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.63 years. Under Daniel's leadership, the company delivered a total shareholder return of -86%.Price Target Changed • Mar 09Price target raised to US$8.13Up from US$7.33, the current price target is an average from 3 analysts. The new target price is 59% above the current share price of US$5.10. As of last close, the stock is up 223% over the past year.Is New 90 Day High Low • Jan 30New 90-day high: US$7.71The company is up 103% from its price of US$3.79 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.분석 기사 • Jan 28What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?If you want to know who really controls OncoSec Medical Incorporated ( NASDAQ:ONCS ), then you'll have to look at the...Is New 90 Day High Low • Jan 12New 90-day high: US$6.81The company is up 75% from its price of US$3.90 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 14% over the same period.Is New 90 Day High Low • Dec 17New 90-day high: US$6.65The company is up 48% from its price of US$4.50 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 07New 90-day high: US$5.11The company is up 27% from its price of US$4.01 on 07 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ONCS.Q 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ONCS.Q 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장OncoSec Medical 배당 수익률 vs 시장ONCS.Q의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ONCS.Q)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.0%업계 평균 (Biotechs)2.0%분석가 예측 (ONCS.Q) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ONCS.Q 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ONCS.Q 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ONCS.Q 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ONCS.Q 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/06/28 22:56종가2023/06/28 00:00수익2023/01/31연간 수익2022/07/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스OncoSec Medical Incorporated는 9명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관James MolloyAlliance Global PartnersThomas ShraderBTIGRaghuram SelvarajuH.C. Wainwright & Co.6명의 분석가 더 보기
공고 • Jun 16+ 2 more updatesOncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial OfficerOncoSec Medical Incorporated announced that on June 12, 2023, George Chi was terminated for cause as an employee and Chief Financial Officer of the company, effective immediately.
공고 • Jun 03OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price RequirementOn June 1, 2023, OncoSec Medical Incorporated (the Company") received notice (the Notice") from the Nasdaq Stock Market LLC (Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the listing of the Company's common stock, which will continue to trade at this time on the Nasdaq Capital Market under the symbol ONCS." In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until November 28, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180 calendar day period. In the event the Company does not regain compliance by November 28, 2023, the Company may be eligible for an additional 180 calendar day grace period if it meets the continued listing requirement for market value of publicly held shares ($1 million) and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not regain compliance within the allotted compliance period(s), Nasdaq will provide notice that the Company's common stock will be subject to delisting from the Nasdaq Capital Market. In that event, the Company may appeal such delisting determination to a hearings panel. The Company intends to monitor the closing bid price of its common stock and consider options to resolve its noncompliance with the minimum bid price requirement.
공고 • May 19OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,408,384 Price\Range: $0.945 Discount Per Security: $0.0709 Transaction Features: Registered Direct Offering
공고 • May 17Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical ProgramOncoSec Medical Incorporated announced a Type C meeting held with the US Food and Drug Administration (FDA) on May 15, 2023. The purpose of the meeting was to discuss the trial design for a planned randomized, open-label Phase 2 clinical trial in patients with high-risk, resectable melanoma to evaluate the neoadjuvant treatment combination of the Company's tavokinogene telseplasmid, a plasmid encoding human interleukin 12 (IL-12), administered intratumorally by electroporation (TAVO(TM)-EP) with intravenous KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy. The meeting with the FDA represents an important next step on the Company's path to pursue clinical development of TAVO(TM)-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting. The Company discussed with the FDA the proposed design of a global randomized Phase 2 trial, which includes a primary endpoint of pathological complete response (pCR) rate and secondary endpoints including event-free survival (EFS) and pathological major response (pMR) rate. As discussed with the FDA, a single arm run-in stage is planned to confirm the appropriate neoadjuvant dosing schedule and allow the collection of mechanistic biomarker data to further evaluate the mechanism of action of TAVO(TM-EP as a trigger for anti-tumor immune effector functions. The Company's discussion with the FDA follows the release of interim data from an ongoing investigator-sponsored trial (IST) led by Dr. Ahmad Tarhini at the H. Lee Moffit Cancer Center & Research Institute evaluating TAVO(TM)- EP in combination with intravenous nivolumab, which showed encouraging clinical and pathological response rates. The Company appreciates the productive meeting with the FDA and the agency's feedback on the trial design and potential strategies for future registrational paths.
Board Change • Jan 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Stephany Foster was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Oct 04OncoSec to cut workforce by 45% as part of corporate restructuringOncoSec Medical (NASDAQ:ONCS) on Tuesday said it would reduce its workforce by about 45% as part of a restructuring intended to focus expenses on the development of its lead clinical candidate Tavo. The company is evaluating Tavo in a phase 2b trial called KEYNOTE-695 for the treatment of metastatic melanoma, the most serious type of skin cancer. "Since joining as CEO my focus has been on reviewing all aspects of our technology and pipeline. This led to the conclusion that an operational restructuring and strategic pipeline refocus is the best course of action," ONCS top boss Robert Arch said in a statement. The company said results of the KEYNOTE-695 trial's secondary goal was expected in Q4 of this year, while results from the main goal was expected in Q1 2023. ONCS stock earlier closed -2% at $0.49.
Price Target Changed • Apr 27Price target decreased to US$5.00Down from US$10.00, the current price target is provided by 1 analyst. New target price is 536% above last closing price of US$0.79. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.99 next year compared to a net loss per share of US$1.37 last year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim DeMesa was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Mar 17Price target decreased to US$5.00Down from US$9.50, the current price target is provided by 1 analyst. New target price is 404% above last closing price of US$0.99. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$1.37 next year compared to a net loss per share of US$1.37 last year.
Board Change • Dec 15Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Chairperson Margaret Dalesandro was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Executive Departure • Aug 18Interim CEO & COO Brian Leuthner has left the companyOn the 13th of August, Brian Leuthner's tenure as Interim CEO & COO of the company ended after less than a year in the role. As of June 2021, Brian still personally held 34.39k shares (US$97k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.92 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Brian's leadership, the company delivered a total shareholder return of -20%.
Breakeven Date Change • Aug 01Forecast to breakeven in 2024The 3 analysts covering OncoSec Medical expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$71.1m in 2024. Average annual earnings growth of 54% is required to achieve expected profit on schedule.
Executive Departure • Jun 29President, CEO & Director Daniel O'Connor has left the companyOn the 25th of June, Daniel O'Connor was replaced as CEO by Brian Leuthner after 3.6 years in the role. As of March 2021, Daniel still personally held 80.52k shares (US$384k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.63 years. Under Daniel's leadership, the company delivered a total shareholder return of -86%.
Price Target Changed • Mar 09Price target raised to US$8.13Up from US$7.33, the current price target is an average from 3 analysts. The new target price is 59% above the current share price of US$5.10. As of last close, the stock is up 223% over the past year.
Is New 90 Day High Low • Jan 30New 90-day high: US$7.71The company is up 103% from its price of US$3.79 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.
분석 기사 • Jan 28What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?If you want to know who really controls OncoSec Medical Incorporated ( NASDAQ:ONCS ), then you'll have to look at the...
Is New 90 Day High Low • Jan 12New 90-day high: US$6.81The company is up 75% from its price of US$3.90 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 14% over the same period.
Is New 90 Day High Low • Dec 17New 90-day high: US$6.65The company is up 48% from its price of US$4.50 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 07New 90-day high: US$5.11The company is up 27% from its price of US$4.01 on 07 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.